Skip to main content

Main menu

  • Home
  • Our journals
    • Clinical Medicine
    • Future Healthcare Journal
  • Subject collections
  • About the RCP
  • Contact us

Clinical Medicine Journal

  • ClinMed Home
  • Content
    • Current
    • Ahead of print
    • Archive
  • Author guidance
    • Instructions for authors
    • Submit online
  • About ClinMed
    • Scope
    • Editorial board
    • Policies
    • Information for reviewers
    • Advertising

User menu

  • Log in

Search

  • Advanced search
RCP Journals
Home
  • Log in
  • Home
  • Our journals
    • Clinical Medicine
    • Future Healthcare Journal
  • Subject collections
  • About the RCP
  • Contact us
Advanced

Clinical Medicine Journal

clinmedicine Logo
  • ClinMed Home
  • Content
    • Current
    • Ahead of print
    • Archive
  • Author guidance
    • Instructions for authors
    • Submit online
  • About ClinMed
    • Scope
    • Editorial board
    • Policies
    • Information for reviewers
    • Advertising

Anaemia of chronic disease

Jonathan Cullis
Download PDF
DOI: https://doi.org/10.7861/clinmedicine.13-2-193
Clin Med April 2013
Jonathan Cullis
Salisbury NHS Foundation Trust, Salisbury
Roles: consultant haematologist
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: jonathan.cullis@salisbury.nhs.uk
  • Article
  • Figures & Data
  • Info & Metrics
Loading
Key Words
  • anaemia of chronic disease
  • erythropoietin
  • hepcidin
  • inflammation
  • iron

Key points

Anaemia of chronic disease is common and its diagnosis should prompt the search for an underlying systemic disorder if none is obvious

It is important to exclude other causes of anaemia, especially iron deficiency

Treatment of the underlying cause may improve anaemia, but other treatment options include erythropoietin and parenteral iron; serum ferritin is a poor predictor of response to intravenous iron

If erythropoietin is used, the lowest dose that avoids the need for blood transfusion but keeps haemoglobin at, <120 g/l should be used

Future research is likely to focus on inhibition of hepcidin, a polypeptide produced in the liver in response to inflammatory stimuli, which produces a state of ‘functional iron deficiency’ – one of the key mechanisms in anaemic of chronic disease

Anaemia of chronic disease (ACD), sometimes known as anaemia of inflammation, is the second most common form of anaemia worldwide1 and is seen in a variety of conditions, including cancer, autoimmune conditions and infections (Box 1). Recent years have seen significant advances in understanding the pathogenesis of ACD, and the aim of this article is to briefly review these and to provide a practical guide to the diagnosis and management of ACD.

Box 1.

Diseases associated with anaemia of chronic disease


Embedded Image

Pathogenesis of ACD

The conditions associated with ACD share features of acute or chronic immune activation, with immune mechanisms significantly contributing to the observed anaemia. Indeed, anaemias associated with other conditions such as heart failure, old age and obesity may also be caused, at least in part, by subtle proinflammatory changes.2–4

The low serum levels of iron usually seen in patients with ACD are now known to be mediated by the polypeptide hepcidin, which is produced in the liver and plays a key role in iron balance and transport.1 Production of hepcidin is increased by inflammatory cytokines, particularly interleukin (IL) 6, as well as in conditions of iron overload,1 whereas levels reduce in iron deficiency. Hepcidin acts by binding to ferroportin and blocking iron export from macrophages and hepatocytes. At the same time, iron absorption by duodenal enterocytes is downregulated. The combined effect is to produce a state of ‘functional iron deficiency’ (FID) (Fig 1).

Fig 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig 1.

Mechanisms of anaemia in anaemia of chronic disease. EPO = erythropoietin; IFN = interferon; IL = interleukin; TNF = tumour necrosis factor.

In ACD, the normal response of increasing production of erythropoietin (EPO) in response to decreasing levels of haemoglobin (Hb) is blunted, possibly mediated through increased levels of IL-1 and tumour necrosis factor alpha (TNF-α). At the same time, EPO-induced proliferation and differentiation of early erythroid precursors is reduced. Finally, limited evidence supports a reduction in red cell survival in patients with ACD.

Diagnosis of ACD

Diagnosis of ACD may be relatively straightforward in a patient with an existing diagnosis of a chronic inflammatory or malignant disorder, but may be more challenging where such a condition is not known to be present. The anaemia is typically normochromic and normocytic, but it may become microcytic as the disease progresses.1 Other causes of anaemia need to be excluded,1,5 including nutritional deficiencies, haemoglobinopathies, haemolysis, hypogonadism, hypothyroidism, myelodysplastic syndrome (MDS), drug effects and recurrent phlebotomy. The reticulocyte count is low. Presence of inflammation may be inferred from leucocytosis, thrombocytosis and inflammatory markers.

Exclusion of iron-deficiency anaemia (IDA) is important in the work up of patients with ACD, although the conditions frequently co-exist: many patients with ACD have a state of FID and they may respond to intravenous iron supplementation even though body iron stores are ‘adequate’.6 Measurement of serum ferritin is of limited value, as ferritin is an acute-phase protein and levels are increased in the presence of inflammation. In patients with anaemia of chronic kidney disease (CKD), improvements in Hb levels are seen following intravenous iron, even in those with ferritin levels of 500–1,200 ng/ml.7 As a general rule, however, ferritin levels of <100 ng/ml in patients with ACD should be taken to indicate coexistent IDA and predict a high likelihood of response to iron supplementation.

Serum iron levels and transferrin saturation are decreased in patients with ACD, and transferrin levels are increased in IDA but normal or decreased in ACD. However, transferrin saturation has poor sensitivity and specificity when used in isolation. Although Perl's stain of a bone-marrow biopsy remains the gold standard for assessment of iron status, the process is invasive and of little value in diagnosis of ACD, although bone marrow biopsy may exclude other causes of anaemia such as MDS.

Assay of serum transferrin receptor (sTfR) has been proposed as a tool for distinguishing ACD from IDA,8 as levels do not vary from steady state in the former, but are increased in the latter. However, the assay is neither widely available nor standardised. The ratio of sTfR to the log ferritin value may be of more value in the diagnosis of ACD,9 with values of <1 making ACD likely, whereas ratios of >2 suggest that iron stores are deficient, with or without ACD. The new red-cell indices reticulocyte haemoglobin content (CHr) and percentage hypochromic red cells (%HYPO), which are available on some modern blood-count analysers, may also contribute to the diagnosis of ACD by providing information about iron supply to red-cell precursors and particularly may help to decide whether iron supplementation will improve haemoglobinisation in individual patients.10

Measurement of hepcidin may prove to be useful in the diagnosis of ACD; hepcidin can be assayed using mass spectrometry or immunoassay, with several assays now commercially available. Increased levels of hepcidin are found in a wide variety of inflammatory and malignant conditions, but it is important to note that levels of hepcidin fall in patients with co-existent ACD and IDA, as the inflammation-induced increase in hepcidin will be opposed by the effects of iron deficiency.6 As one of the long-term effects of hepcidin is to produce iron deficiency through suppression of intestinal iron absorption, the use of hepcidin levels to diagnose ACD will have to be evaluated carefully.

Overall, no uniform laboratory criteria for the diagnosis of ACD exist. Therefore, it may be necessary to assess several laboratory parameters together with the clinical picture when making a diagnosis (Table 1).

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table 1.

Use of laboratory investigations in the differential diagnosis of ACD.

Management of ACD

Anaemia can independently impact on morbidity and mortality in patients with conditions associated with ACD,11,12 as well as affecting quality of life, although whether measures to improve Hb levels in ACD will improve survival remains to be seen.13 Treatment of the underlying condition – for example, the use of steroids in polymyalgia rheumatica or TNFα inhibitors in inflammatory bowel disease – will often result in improvement of anaemia; indeed, improvements in the management of many conditions that cause ACD, including HIV and rheumatoid arthritis, mean that specific correction of anaemia is often unnecessary. However, in patients with other conditions, such as advanced cancer or cardiac failure, the degree of anaemia reflects the severity of the underlying cause, so correction may improve both prognosis and quality of life.

Blood transfusion

Transfused blood remains a precious resource and also carries risks of transfusion-transmitted infection, alloimmunisation and haemosiderosis. Blood transfusion should therefore be reserved for patients with severe and life-threatening anaemia.

Erythropoiesis-stimulating agents

The blunted EPO response and relative insensitivity of erythroid precursors to endogenous EPO make the use of erythropoiesis-stimulating agents (ESAs) a rational approach to management of ACD, and there is considerable experience with these agents in the setting of renal disease, cancer and, more recently, anaemia of heart failure.14,15 Several recombinant human EPOs are available, with epoetin alfa (Eprex) and darbepoetin (Aranesp) used in the UK, alongside biosimilars such as biosimilar epoetin alfa (Binocrit).

Patients with ACD caused by cancer, rheumatoid arthritis and HIV infection frequently gain benefit from EPO. The greatest experience comes from patients with cancer, in whom there is now good evidence of improved Hb levels, a reduced need for transfusions and improved quality of life.13,14 However predicting which patients will respond to EPO is not straightforward, and it is important, as discussed earlier, to rule out concomitant iron deficiency that may limit the response to EPO.

However, concerns exist due to data showing possible adverse effects associated with ESAs – for example, cardiovascular risk, especially the risk of thrombosis, may be increased – and authorities now recommend maintaining Hb levels at ≤120 g/l to minimise this risk.16 Data also suggest an increased risk of tumour recurrence in patients with cancer who receive ESAs, and the US Food and Drug Administration recommends avoiding the use of ESAs in patients with cancers of the breast, head and neck, those with non-small cell lung cancer and those with active malignancies not receiving chemotherapy or radiotherapy,17 while the National Institute for Health and Clinical Excellence (NICE) in the UK limits use to women with ovarian cancer receiving platinum-based chemotherapy or patients who cannot receive blood transfusions,18 although a recent meta-analysis casts doubt on these recommendations.19

Parenteral iron therapy

The FID present in many patients with ACD and the frequent co-existence of true IDA and ACD make iron supplementation an attractive method for the treatment of ACD.6 Safer forms of parenteral iron have become available in recent years and are widely used in conjunction with ESAs in the management of renal anaemia. Indeed, there is mounting evidence that parenteral iron in addition to ESAs may enhance response to the latter in patients with cancer-associated anaemia.20 A recent study even hypothesised that iron supplementation may reduce the thrombotic risk associated with ESAs by reducing the platelet count.21

It is recommended that iron status is assessed periodically in patients receiving ESAs, and consideration should be given to administration of intravenous iron in patients who show suboptimal response to EPO. Limited studies show that intravenous iron given alone without ESAs may improve Hb levels in patients with ACD in association with cancer and heart failure, but further research is needed in this regard. Theoretical concerns about the increased risk of infection in patients given intravenous iron have not been borne out.

Future directions

Ongoing research is investigating the effects of inhibition of hepcidin – either through direct antibody-mediated approaches or by indirect inhibition through other small molecules in the hepcidin/ferroportin pathway. An intriguing observation is the association of ACD with vitamin D deficiency in a large population-based survey in the USA,22 although further studies will need to be performed to determine whether vitamin D supplementation can suppress inflammation and ameliorate anaemia in the setting of inflammation.

  • © 2013 Royal College of Physicians

References

  1. ↵
    1. Weiss G,
    2. Goodnough LT
    . Anemia of chronic disease. N Engl J Med 2005; 352: 1011–23.
    OpenUrlCrossRefPubMed
  2. ↵
    1. Kleijn L,
    2. Belonje AM,
    3. Voors AA,
    4. et al.
    Inflammation and anaemia in a broad spectrum of patients with heart failure. Heart 2012; 98: 1237–41. doi:10.1136/heartjnl-2012-301954
    OpenUrlAbstract/FREE Full Text
    1. Ferrucci L,
    2. Balducci L.
    Anemia of aging: the role of chronic inflammation and cancer. Semin Hematol 2008; 45: 242–9. doi:10.1053/j.seminhematol.2008.06.001
    OpenUrlCrossRefPubMed
  3. ↵
    1. Ausk KJ,
    2. Ioannou GN
    . Is obesity associated with anemia of chronic disease? A population-based study. Obesity 2008; 16: 2356–61. doi:10.1038/oby.2008.353
    OpenUrlCrossRefPubMed
  4. ↵
    1. Bloxham E,
    2. Vagadia V,
    3. Scott K,
    4. et al.
    Anaemia in rheumatoid arthritis: can we afford to ignore it? Postgrad Med J 2011; 87: 596–600. doi:10.1136/pgmj.2011.117507
    OpenUrlAbstract/FREE Full Text
  5. ↵
    1. Goodnough LT,
    2. Nemeth E,
    3. Ganz T.
    Detection, evaluation and management of iron-restricted erythropoiesis. Blood 2010; 116: 4754–61. doi:10.1182/blood-2010-05-286260
    OpenUrlAbstract/FREE Full Text
  6. ↵
    1. Coyne DW,
    2. Kapoian T,
    3. Suki W,
    4. et al.
    Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: results of the Dialysis Patients' Response to IV Iron with Elevated Ferritin (DRIVE) Study. J Am Soc Nephrol 2007; 18: 975–84.
    OpenUrlAbstract/FREE Full Text
  7. ↵
    1. Koulaouzidis A,
    2. Said E,
    3. Cottier R,
    4. Saeed AA
    . Soluble transferrin receptors and iron deficiency, a step beyond ferritin. A systematic review. J Gastrointest Liv Dis 2009; 18: 345–52.
    OpenUrl
  8. ↵
    1. Skikne BS,
    2. Punnonen K,
    3. Caldron PH,
    4. et al.
    Improved differential diagnosis of anemia of chronic disease and iron deficiency anemia: a prospective multicenter evaluation of soluble transferrin receptor and the sTfR/log ferritin index. Am J Hematol 2011; 86: 923–7. doi:10.1002/ajh.22108
    OpenUrlCrossRefPubMed
  9. ↵
    1. Thomas C,
    2. Thomas L.
    Biochemical markers and hematologic indices in the diagnosis of functional iron deficiency. Clin Chem 2002; 48: 1066–76.
    OpenUrlAbstract/FREE Full Text
  10. ↵
    1. Nissenson AR,
    2. Goodnough LT,
    3. Dubois RW
    . Anemia: not just an innocent bystander? Arch Intern Med 2003; 163: 1400–4. doi:10.1001/archinte.163.12.1400
    OpenUrlCrossRefPubMed
  11. ↵
    1. Caro JJ,
    2. Salas M,
    3. Ward A,
    4. Goss G.
    Anemia as an independent prognostic factor for survival in patients with cancer: a systematic, quantitative review. Cancer 2001; 91: 2214–21. doi:10.1002/1097-0142(20010615)91:12<2214::AID-CNCR1251>3.0.CO;2-P
    OpenUrlCrossRefPubMed
  12. ↵
    1. Wilson J,
    2. Yao GL,
    3. Raftery J,
    4. et al.
    A systematic review and economic evaluation of epoetin alfa, epoetin beta and darbepoetin alpha in anaemia associated with cancer, especially that attributable to cancer treatment. Health Technol Ass 2007; 11: 1–202.
    OpenUrl
  13. ↵
    1. Littlewood TJ,
    2. Bajetta E,
    3. Nortier JW,
    4. et al.
    Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 2001; 19: 2865–74.
    OpenUrlAbstract/FREE Full Text
  14. ↵
    1. Ngo K,
    2. Kotecha D,
    3. Walters JA,
    4. et al.
    Erythropoiesis-stimulating agents for anaemia in chronic heart failure patients. Cochrane Database Syst Rev 2010; (20):CD007613.
    OpenUrl
  15. ↵
    1. Rizzo JD,
    2. Brouwers M,
    3. Hurley P,
    4. et al.
    American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer. Blood 2010; 116: 4045–59.
    OpenUrlAbstract/FREE Full Text
  16. ↵
    US Food and Drug Administration. Erythropoiesis-stimulating agents (ESAs). Silver Spring, MD: FDA, 2007. www.fda.gov/NewsEvents/Testimony/ucm110908.htm [Accessed 1 February 2013].
  17. ↵
    National Institute for Health and Clinical Excellence (NICE). Erythropoetin (alfa and beta) and darbepoetin for the treatment of cancer-treatment induced anaemia. London: NICE, 2009. www.nice.org.uk/nicemedia/live/11990/40744/40744.pdf [Accessed 27 February 2013].
  18. ↵
    1. Glaspy J,
    2. Crawford J,
    3. Vansteenkiste J,
    4. et al.
    Erythropoiesis stimulating agents in oncology: a study-level meta-analysis of survival and other safety outcomes. Br J Cancer 2010; 102: 301–15. doi:10.1038/sj.bjc.6605498
    OpenUrlCrossRefPubMed
  19. ↵
    1. Littlewood TJ,
    2. Alikhan R.
    The use of intravenous iron in patients with cancer-related anaemia. Br J Haematol 2008; 141: 751–6. doi:10.1111/j.1365-2141.2008.07118.x
    OpenUrlCrossRefPubMed
  20. ↵
    1. Henry DH,
    2. Dahl NV,
    3. Auerbach MA
    . Thrombocytosis and venous thromboembolism in cancer patients with chemotherapy induced anemia may be related to ESA induced iron restricted erythropoiesis and reversed by administration of IV iron. Am J Hematol 2012; 87: 308–10. doi:10.1002/ajh.22262
    OpenUrlCrossRefPubMed
  21. ↵
    1. Perlstein TS,
    2. Pande R,
    3. Berliner R,
    4. Vanasse GJ
    . Prevalence of 25-hydroxyvitamin D deficiency in subgroups of elderly persons with anemia: association with anemia of inflammation. Blood 2011; 117: 2800–6. doi:10.1182/blood-2010-09-309708
    OpenUrlAbstract/FREE Full Text
Back to top
Previous articleNext article

Article Tools

Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Citation Tools
Anaemia of chronic disease
Jonathan Cullis
Clinical Medicine Apr 2013, 13 (2) 193-196; DOI: 10.7861/clinmedicine.13-2-193

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Anaemia of chronic disease
Jonathan Cullis
Clinical Medicine Apr 2013, 13 (2) 193-196; DOI: 10.7861/clinmedicine.13-2-193
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Pathogenesis of ACD
    • Diagnosis of ACD
    • Management of ACD
    • References
  • Figures & Data
  • Info & Metrics

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • Diagnostics in anaemia of chronic disease in general practice: a real-world retrospective cohort study
  • Google Scholar

More in this TOC Section

  • Autoimmune cytopenias and thrombotic thrombocytopenic purpura
  • Autologous haematopoietic stem cell transplantation (aHSCT) for severe resistant autoimmune and inflammatory diseases – a guide for the generalist
  • Common haemostasis issues in major bleeding and critical illness
Show more CME Haematology

Similar Articles

Navigate this Journal

  • Journal Home
  • Current Issue
  • Ahead of Print
  • Archive

Related Links

  • ClinMed - Home
  • FHJ - Home
clinmedicine Footer Logo
  • Home
  • Journals
  • Contact us
  • Advertise
HighWire Press, Inc.

Follow Us:

  • Follow HighWire Origins on Twitter
  • Visit HighWire Origins on Facebook

Copyright © 2021 by the Royal College of Physicians